ProKidney Reports First Quarter 2026 Financial Results and Business Highlights
ProKidney reported Q1 2026 results with $226k in revenue and a net loss of $42.6 million before noncontrolling interest, driven by $33.8 million in R&D spend. The company ended the quarter with $224.9 million in total liquidity, sufficient to fund operations into mid-2027.
Key figures
- Revenue
- 226000
- Ga expenses
- 11317000
- Rd expenses
- 33842000
- Total liquidity
- 224900000
- Cash and equivalents
- 101895000
- Marketable securities
- 123049000
- Total shares outstanding
- 301953977
- Shares outstanding class a
- 141980643
- Shares outstanding class b
- 159973334
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.